Encorafenib
About
Therapy type: Targeted therapy
Therapy strategy: B-RAF inhibition
Mappings
NCI Thesaurus: Encorafenib (ncit:C98283)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Non-Small Cell Lung Cancer | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Non-Small Cell Lung Cancer | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin | |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib | |
| Sensitivity (+) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib |